Skip to content
Calculator
Evidence: HighPeptideFDA ApprovedHepcidin mimeticFDA-approved · MimryloReplaces repeated phlebotomy

Rusfertide

A peptide that copies the hormone controlling iron traffic, approved to treat polycythaemia vera by starving red-cell production of its raw material

Polycythaemia vera makes too many red cells, and the standard answer has been to remove blood repeatedly. Rusfertide mimics hepcidin, locks iron inside the cells that store it, and leaves the marrow short of it. It was approved in 2026 as Mimrylo.

Manufacturer's recommended dosing (FDA label): Start 19 mg; adjust in steps from 9.5 to a maximum of 108 mg; doses above 54 mg need two injections, and above 82 mg are split across day 1 and day 4 or 5, Once weekly, Subcutaneous Details ↓

Overview

What is it?

Hepcidin controls iron's only exit from a cell: it binds ferroportin, the sole iron exporter, and has it degraded, so iron stays in gut cells and macrophages. Rusfertide copies that signal, leaving the marrow short of the iron it needs to build red cells — the point in a disease defined by building too many.

The trial that made the case is REVIVE. Seventy patients with phlebotomy-dependent polycythaemia vera went through 28 weeks of dose-finding, then 59 were randomised to rusfertide or placebo for 12 weeks; beforehand they had averaged nearly nine phlebotomies a year.

The phase 3 trial, VERIFY, is described in the Mimrylo label. It randomised 293 adults who still needed frequent phlebotomies despite standard care, which for most meant phlebotomy alone or with hydroxyurea. Between weeks 20 and 32, 76.9% on rusfertide no longer qualified for phlebotomy, against 32.9% on placebo, and the average number of phlebotomies over 32 weeks fell to 0.53 from 1.82. Fatigue scores also improved slightly more than on placebo.

A later study shows how fast the effect arrives. In 20 patients whose haematocrit was above 48% despite treatment, 40 mg twice weekly brought 85% below 45% by week 8, with a median of 4.9 weeks to the first reading under 45%. Nobody needed a phlebotomy while on treatment.

The trade-offs are listed in the label. Injection-site reactions affected 56% in VERIFY's controlled period, though only 2 patients stopped for them. Platelet counts rose by an average of 31% within four weeks, exceeding 600 × 10⁹/L in 36%, so blood counts are checked every 2 to 4 weeks while the dose is adjusted. Anaemia, the mechanism overshooting, was the commonest reason to lower the dose. A thorough QT study at 90 mg found no effect on heart rhythm.

The same mechanism was tried in the opposite disease, HFE-related haemochromatosis, where too little hepcidin lets iron build up: a phase 2 trial gave 10 mg weekly for 24 weeks. The approved indication is polycythaemia vera only.

19 mg
Label starting dose
once weekly, subcutaneous · Mimrylo label
4.9 weeks
Median time to haematocrit under 45%
in poorly controlled disease · PMID 41175501
Science

Mechanism of Action

Rusfertide is a hepcidin mimetic: it blocks ferroportin, the iron exporter, so less iron reaches the marrow and fewer red cells are made (label).

🔒

Ferroportin blocked

Like hepcidin, it binds ferroportin and keeps iron inside gut cells and macrophages.

🩸

Less iron for red cells

With less iron available, the marrow makes fewer red cells and haematocrit falls; serum iron and transferrin saturation drop with dose.

⏱️

Weekly kinetics

After 19 mg, levels peak at about 24 hours, the half-life is about 28.6 hours, and steady state is reached after about three weekly doses (label).

Evidence

Published Research

These are the trials that describe rusfertide, read from their PubMed abstracts: the phase 2 in polycythaemia vera, a rapid-control study, the haemochromatosis trial and a pharmacology study.

Human2024

REVIVE, the phase 2

70 patients with phlebotomy-dependent polycythaemia vera entered 28 weeks of dose-finding; 59 were then randomised to rusfertide or placebo for 12 weeks. The endpoint combined haematocrit control, no phlebotomy and completing the regimen. Participants had averaged 8.7 phlebotomies a year beforehand.

PMID: 38381675
Human2025

How quickly it works

20 patients with haematocrit above 48% took 40 mg twice weekly until it fell below 45%, then weekly. By week 8, 85% were below 45% and 95% had fallen at least 5 points; the median time to the first reading under 45% was 4.9 weeks. No patient needed a phlebotomy during treatment.

PMID: 41175501
Human2023

The opposite disease

An open-label phase 2 trial at nine US and Canadian centres gave 10 mg weekly for 24 weeks to adults with HFE-related haemochromatosis on maintenance phlebotomy, keeping transferrin saturation under 40%.

PMID: 37863080
Human2024

What the body does with it

Healthy adults received 10 to 60 mg of the lyophilised formulation or a 20 mg prefilled syringe, crossover. Peak concentration came at 24 hours for lower doses and 2 to 4 hours at the top doses; terminal half-life ran from 19.6 to 57.1 hours.

PMID: 39546273
Human2025

Injection site and repeat dosing

In 18 healthy volunteers given 60 mg weekly for five weeks, peak levels after the first dose differed by site (abdomen 547, thigh 387, arm 560 ng/mL) but total exposure and the fall in haematocrit did not; there were no serious adverse events.

PMID: 39888264
Human2024

Aqueous formulation: single doses

In healthy men, single doses of 1 to 80 mg were well tolerated with no serious or severe adverse events; exposure rose less than in proportion to dose, and serum iron and transferrin saturation fell with dose.

PMID: 38785334
Human2025

Thorough QT study

In 60 healthy adults, a 90 mg dose had no clinically relevant effect on heart rate or conduction; placebo-corrected QTcF changes ran from -2.0 to 1.8 ms, while the moxifloxacin control raised it by about 12 ms.

PMID: 41033871
Dosing

Dosing Data

Mimrylo starts at 19 mg once a week under the skin and is adjusted, no sooner than every two weeks, within 9.5 to 108 mg to keep haematocrit below 45%.

Prescription for polycythaemia vera. Blood counts every 2 to 4 weeks during dose changes, because platelets can rise and anaemia can develop.
ProtocolDoseFrequencyDurationRoute
Label: erythrocytosis in adults with polycythaemia vera Approved labelMIMRYLO (rusfertide) for injection Prescribing Information, sections 1, 2, 5, 6, 12 and 14 (DailyMed version 2, effective August 28, 2026)Start 19 mg; adjust in steps from 9.5 to a maximum of 108 mg; doses above 54 mg need two injections, and above 82 mg are split across day 1 and day 4 or 5Once weeklyOngoing, with dose changes at least 2 weeks apartSubcutaneous
Study: suboptimally controlled disease (haematocrit above 48%) Human studyPMID 4117550140 mgTwice weekly8 weeksSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Stepped doses
Mimrylo is dosed in fixed steps (9.5, 19, 28, 41, 54 mg and up), not by weight; the prescriber moves between steps.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Mimrylo (rusfertide kit): For injection: 9.5 mg, 19 mg, 28 mg, 41 mg, and 54 mg of rusfertide as a lyophilized powder in single-dose vials for reconstitution. Forms the label lists: single-dose vials.

Source: Mimrylo (rusfertide kit) label, section 3 (DailyMed version 2, effective August 28, 2026).

Mixing a vial: a worked example

The approved product Mimrylo (rusfertide kit) is a powder that is mixed before use, with the liquid and volume its label names. Follow the label, not a general example. Its label says: “MIMRYLO must be reconstituted using the provided diluent prefilled syringe.”

Source: Mimrylo (rusfertide kit) label, sections 2 and 3 (DailyMed version 2, effective August 28, 2026).

Storage before and after mixing

Before mixing or first use: “Store at room temperature between 20°C to 25°C (68°F to 77°F).” “Store in the original carton to protect from light.” “Do not freeze.”

After mixing or first use: “After reconstitution, MIMRYLO may be stored at room temperature between 20°C to 25°C (68°F to 77°F) for up to 4 hours.” “Discard reconstituted solution if not used within 4 hours.”

Source: Mimrylo (rusfertide kit) label, sections 16 and 2 (DailyMed version 2, effective August 28, 2026).

How it is taken

As the approved label gives it: Subcutaneous (Once weekly; Label: erythrocytosis in adults with polycythaemia vera).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of 28.6 ± 11.3 hours (mean plasma elimination). After about five half-lives almost none is left.

How long the doses were given: Label: erythrocytosis in adults with polycythaemia vera: Ongoing, with dose changes at least 2 weeks apart.

When effects appear: unknown; no source on this page gives a time to effect for Rusfertide. Results reported in the studies are under Published Research.

Source: half-life: Mimrylo prescribing information, section 12.3 (DailyMed version 2, effective August 28, 2026; read September 30, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Injection-site reactions, usual for a weekly subcutaneous peptide; Iron and transferrin saturation fall by design; Haemoglobin and haematocrit fall, which the dose is titrated against; No boxed warning and no drug interactions section on the label. Full list and cautions ↓

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Rusfertide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the trials above and the Mimrylo label”).

Interactions

  • no drug: the label carries no drug interactions section and no boxed warning

Every peptide's record, with its source: the interaction matrix.

Source: Mimrylo (rusfertide) for injection, US prescribing information. DailyMed version 2, effective August 28, 2026, read September 30, 2026.

Checking what you bought

Unknown: no published independent test of Rusfertide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Rusfertide's expected mass, 2,442.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (FDA-approved as Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythaemia vera). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the trials above and the Mimrylo label.

● Injection-site reactions, usual for a weekly subcutaneous peptide
● Iron and transferrin saturation fall by design
● Haemoglobin and haematocrit fall, which the dose is titrated against
● No boxed warning and no drug interactions section on the label

Contraindications & Cautions

A prescription drug for a disease managed by haematologists.

● Anyone outside specialist care — the dose is titrated against haematocrit readings
● Anyone expecting it to treat the underlying clone; it controls erythrocytosis, not the JAK2-driven disease
● Self-treatment for iron overload, which is investigational and was studied at a different dose
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is rusfertide?

A synthetic peptide that mimics hepcidin, the hormone controlling iron traffic. It binds ferroportin so iron stays locked inside cells instead of reaching the blood.

?What is it approved for?

Erythrocytosis in adults with polycythaemia vera, as Mimrylo. The label starts at 19 mg weekly under the skin, within a 9.5 to 108 mg range.

?Does it replace phlebotomy?

That is the aim. In a later study no patient needed a phlebotomy while on treatment.

?Why does restricting iron help?

The marrow cannot build red cells without iron. Rusfertide leaves the JAK2-driven clone alone and removes its raw material.

?Does rusfertide replace phlebotomy?

For most patients in VERIFY it did between weeks 20 and 32: 76.9% on rusfertide no longer qualified for phlebotomy, against 32.9% on placebo, and phlebotomies over 32 weeks averaged 0.53 against 1.82. It was added to existing care, which for many included hydroxyurea or interferon.

?Where is it injected?

Under the skin of the abdomen, thigh or upper arm. In healthy volunteers, first-dose peaks differed by site but total exposure and the effect on haematocrit did not, and the label reports similar steady-state exposure at all three sites.

?Can it be used in pregnancy?

The label warns that, based on animal studies, it can cause fetal harm, and advises women who could become pregnant to use effective contraception.

?Why are blood counts checked so often?

Platelets rose by an average of 31% within four weeks of starting, and anaemia was the most common reason to lower the dose, so the label asks for a complete blood count every 2 to 4 weeks while the dose is being adjusted.

Bibliography

References

  1. [fda-pi] Mimrylo (rusfertide) for injection Prescribing Information, sections 1 and 2. Takeda Pharmaceuticals America (DailyMed set 101aff01, version 2, effective August 28, 2026; read September 30, 2026).
  2. [pubmed] Kremyanskaya M, et al. "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera." N Engl J Med, 2024;390(8):723-735. PMID: 38381675.
  3. [pubmed] Chew LP, et al. "Rusfertide rapidly decreases hematocrit in patients with suboptimally controlled polycythemia vera." Leuk Res, 2025;159:108132. PMID: 41175501.
  4. [pubmed] Kowdley KV, et al. "Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial." Lancet Gastroenterol Hepatol, 2023;8(12):1118-1128. PMID: 37863080.
  5. [pubmed] Modi NB, et al. "Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers." Drugs R D, 2024;24(4):539-552. PMID: 39546273.
  6. [pubmed] Modi NB, et al. "Evaluation of Rusfertide, a Hepcidin Mimetic, on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover Thorough QT Study in Healthy Participants." Clin Ther, 2025;47(11):1043-1052. PMID: 41033871.
  7. [other] US FDA, Drugs@FDA (openFDA): MIMRYLO (rusfertide), Takeda, NDA 220605, prescription, powder in 9.5, 28, 41 and 54 mg base vials. Read September 30, 2026.
  8. [pubmed] Modi NB, et al. "Multiple-Dose Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous Rusfertide, a Hepcidin Mimetic, in Healthy Subjects." Clin Pharmacol Drug Dev, 2025;14(4):311-323. PMID: 39888264.
  9. [pubmed] Modi NB, et al. "Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study." Eur J Haematol, 2024;113(3):340-350. PMID: 38785334.

Sources & Citations

Studies were read from their PubMed abstracts; the Mimrylo label (DailyMed version 2, effective August 28, 2026) was read September 30 and October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-09-30